AstraZeneca has sold off marketing and development rights to another one of its pipeline assets.
This time it’s Takeda that’s stepping up, inking a deal package totaling $400 million for development and commercialization rights to its home grown MEDI1341, an alpha-synuclein antibody designed to combat Parkinson’s disease.